MINI FUTURE LONG - MODERNA | Market Closed - Deutsche Boerse AG 03:50:37 2024-06-14 pm EDT | ||
| 8.32 EUR | -5.02% |
|
| Current month | -2.12% | ||
| 1 month | +15.56% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 8.32 | -5.02% |
| 24-06-13 | 8.76 | -1.79% |
| 24-06-12 | 8.92 | -1.98% |
| 24-06-11 | 9.1 | +0.78% |
| 24-06-10 | 9.03 | -2.80% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 03:50 pm EDT
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PN0QRX |
| ISIN | DE000PN0QRX7 |
| Date issued | 2020-05-28 |
| Strike | 51.19 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.65 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 39.59 € |
|---|---|
| Lowest since issue | 1.23 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140
USD
Average target price
145.2
USD
Spread / Average Target
+3.67%
- Stock Market
- Certificates
- Certificat
